PFE – Pfizer Inc.

PFE — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

2.73

Margin Of Safety %

Put/Call OI Ratio

0.78

EPS Next Q Diff

-0.06

EPS Last/This Y

-0.25

EPS This/Next Y

-0.08

Price

28.27

Target Price

28.99

Analyst Recom

2.62

Performance Q

15.48

Upside

-65.1%

Beta

0.27

Ticker: PFE

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-09-11	PFE	27.7	0.78	0.25	2521432
2026-09-14	PFE	27.73	0.79	0.44	2476829
2026-09-15	PFE	27.54	0.78	0.28	2505212
2026-09-16	PFE	27.48	0.78	0.59	2516778
2026-09-17	PFE	27.63	0.79	0.26	2531647
2026-09-18	PFE	27.61	0.78	0.45	2547680
2026-09-21	PFE	27.75	0.76	0.77	1981198
2026-09-22	PFE	27.9	0.78	0.22	2043999
2026-09-23	PFE	28.15	0.76	0.26	2083902
2026-09-24	PFE	28.42	0.75	0.43	2101276
2026-09-25	PFE	28.68	0.75	0.34	2144493
2026-09-28	PFE	28.77	0.75	0.37	2106108
2026-09-29	PFE	28.72	0.75	0.28	2130026
2026-09-30	PFE	28.53	0.75	0.35	2148875
2026-10-01	PFE	28.13	0.75	0.71	2170649
2026-10-02	PFE	27.8	0.75	1.68	2182413
2026-10-05	PFE	27.41	0.80	0.29	2184043
2026-10-06	PFE	27.49	0.80	0.52	2204082
2026-10-07	PFE	27.99	0.80	0.24	2228296
2026-10-08	PFE	27.83	0.78	0.38	2255649
2026-10-09	PFE	28.27	0.78	0.28	2265970
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-09-11	PFE	27.70	-12.8	12546.4	2.98
2026-09-14	PFE	27.73	-12.8	12525.3	2.98
2026-09-15	PFE	27.54	-12.8	12424.8	2.98
2026-09-16	PFE	27.54	-12.8	12424.8	2.98
2026-09-17	PFE	27.63	-12.8	12610.4	2.98
2026-09-18	PFE	27.61	-12.8	12504.0	2.98
2026-09-21	PFE	27.75	-12.8	12567.6	2.98
2026-09-22	PFE	27.93	-12.8	12620.3	2.98
2026-09-23	PFE	28.17	-12.8	12646.1	2.98
2026-09-24	PFE	28.43	-12.8	12650.4	2.98
2026-09-25	PFE	28.68	-12.8	12662.6	2.98
2026-09-28	PFE	28.73	-12.8	12550.8	2.97
2026-09-29	PFE	28.73	-12.8	12525.1	2.97
2026-09-30	PFE	28.53	-12.8	12422.3	2.97
2026-10-01	PFE	28.12	-12.8	12313.3	2.97
2026-10-02	PFE	27.80	-12.8	12148.0	2.97
2026-10-05	PFE	27.41	-12.8	12314.5	2.97
2026-10-06	PFE	27.48	-12.8	12557.3	2.97
2026-10-07	PFE	28.00	-12.8	12785.5	2.97
2026-10-08	PFE	27.83	-13.6	12430.9	2.97
2026-10-09	PFE	28.27	-13.6	12756.8	2.97
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-09-11	PFE	2.18	-0.40	2.66
2026-09-14	PFE	2.18	-0.46	2.66
2026-09-15	PFE	2.18	-0.46	2.66
2026-09-16	PFE	2.18	-0.46	2.66
2026-09-17	PFE	2.18	-0.46	2.66
2026-09-18	PFE	2.18	-0.46	2.66
2026-09-21	PFE	2.18	-0.47	2.66
2026-09-23	PFE	2.18	-0.47	2.66
2026-09-24	PFE	2.18	-0.47	2.66
2026-09-25	PFE	2.18	-0.47	2.73
2026-09-28	PFE	2.18	-0.47	2.73
2026-09-29	PFE	2.18	-0.47	2.73
2026-09-30	PFE	2.18	-0.47	2.73
2026-10-01	PFE	2.18	-0.47	2.73
2026-10-02	PFE	2.18	-0.47	2.73
2026-10-05	PFE	2.18	-0.46	2.73
2026-10-06	PFE	2.18	-0.46	2.73
2026-10-07	PFE	2.18	-0.46	2.73
2026-10-08	PFE	2.18	-0.46	2.73
2026-10-09	PFE	2.18	-0.46	2.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.77

Avg. EPS Est. Current Quarter

0.75

Avg. EPS Est. Next Quarter

0.71

Insider Transactions

2.18

Institutional Transactions

-0.46

Beta

0.27

Average Sales Estimate Current Quarter

15949

Average Sales Estimate Next Quarter

16927

Fair Value

34.4

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

54.2

Max Drawdown 5-Year %

-59

Target Price

28.99

P/E

37.43

Forward P/E

9.76

PEG

P/S

2.53

P/B

1.89

P/Free Cash Flow

14.67

EPS

0.76

Average EPS Est. Cur. Y

2.97

EPS Next Y. (Est.)

2.9

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

6.8

Relative Volume

0.62

Return on Equity vs Sector %

-21.3

Return on Equity vs Industry %

-30.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

12756.8

◆ PFE Healthcare

$28.27

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

8/25

Volume

9/15

Valuation

10/20

TP/AR

0/10

Options

3/10

RSI

55.7

Range 1M

60.6%

Sup Dist

2.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

9/25

Growth

4/30

Estimates

3/20

Inst/Vol

3/15

Options

8/10

EPS Yr

-7.9%

EPS NY

-2.3%

52W%

82.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +23.7% upside

Quality

8/30

Valuation

13/30

Growth

3/25

Stability

3/10

LT Trend

3/5

Upside

+23.7%

Quality

MoS

22%

PFE — P/E HistoricalDrug Manufacturers - General

Pfizer, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 75000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PFE

Latest News

—

Caricamento notizie per PFE…

stock quote shares PFE – Pfizer Inc. Stock Price stock today

news today PFE – Pfizer Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch PFE – Pfizer Inc. yahoo finance google finance

stock history PFE – Pfizer Inc. invest stock market

stock prices PFE premarket after hours

ticker PFE fair value insiders trading

PFE – Pfizer Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PFE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y